A review of the lipid-related effects of fluvastatin
作者： Evagelos N. Liberopoulos , Stella S. Daskalopoulou , Dimitri P. Mikhailidis , Anthony S. Wierzbicki , Moses S. Elisaf
关键词:
摘要: ABSTRACTBackground: Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary secondary prevention trials. This review considers the pharmacology, non-lipid-lowering effects clinical trial evidence of fluvastatin based on a survey PubMed entries.Findings: Recent data show that treatment with is associated variety benefits different high-risk populations along good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic both experimental studies. Furthermore, an extended-release formulation favourable pharmacokinetic profile available.Conclusion: Treatment offers convenient, safe evidence-based approach managing dyslipidaemias preventing events.
informahealthcare.com参考文章(163)
Ikuo Inoue, Sei-ichi Goto, Kasumi Mizotani, Takuya Awata, Toshiyuki Mastunaga, Shin-ichiro Kawai, Takanori Nakajima, Shigeru Hokari, Tugikazu Komoda, Shigehiro Katayama, Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect Life Sciences. ,vol. 67, pp. 863- 876 ,(2000) , 10.1016/S0024-3205(00)00680-9
Stefan Beil, Conrad Pfafferott, Michael Weber, Fluvastatin Lipid-Lowering Effect in Routine Practice Conditions (FLIRT) Clinical Drug Investigation. ,vol. 14, pp. 146- 153 ,(1997) , 10.2165/00044011-199714020-00009
Süleyman Türk, Alaattin Yıldız, Tufan Tükek, Vakur Akkaya, Şükrü Aras, Aydın Türkmen, Ali Rıza Uras, Mehmet Şükrü Sever, The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study. International Urology and Nephrology. ,vol. 32, pp. 713- 716 ,(2001) , 10.1023/A:1015052312866
Luciana Mussoni, Cristina Banfi, Luigi Sironi, Magda Arpaia, Elena Tremoli, None, Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thrombosis and Haemostasis. ,vol. 84, pp. 59- 64 ,(2000) , 10.1055/S-0037-1613968
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. ,vol. 361, pp. 2005- 2016 ,(2003) , 10.1016/S0140-6736(03)13636-7
Bonaventura Clotet, Eugènia Negredo, HIV protease inhibitors and dyslipidemia. Aids Reviews. ,vol. 5, pp. 19- 24 ,(2003)
Takayuki Ito, Uichi Ikeda, Masahisa Shimpo, Ruri Ohki, Masafumi Takahashi, Keiji Yamamoto, Kazuyuki Shimada, HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovascular Drugs and Therapy. ,vol. 16, pp. 121- 126 ,(2002) , 10.1023/A:1015701415588
John A Papadakis, Emanuel S Ganotakis, Indera A Jagroop, Anthony F Winder, Dimitri P Mikhailidis, None, Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease International Journal of Cardiology. ,vol. 69, pp. 237- 244 ,(1999) , 10.1016/S0167-5273(99)00013-3
A. Jardine, H. Holdaas, Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience Journal of Clinical Pharmacy and Therapeutics. ,vol. 24, pp. 397- 408 ,(1999) , 10.1046/J.1365-2710.1999.00252.X
Denise Barilla, Pratapa Prasad, Martine Hubert, Kavita Gumbhir-Shah, Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharmaceutics & Drug Disposition. ,vol. 25, pp. 51- 59 ,(2004) , 10.1002/BDD.378